NASDAQ:INBX Inhibrx Biosciences Q3 2025 Earnings Report $93.41 -1.15 (-1.22%) Closing price 04:00 PM EasternExtended Trading$93.50 +0.09 (+0.09%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inhibrx Biosciences EPS ResultsActual EPS-$2.28Consensus EPS -$2.94Beat/MissBeat by +$0.66One Year Ago EPSN/AInhibrx Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibrx Biosciences Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time6:00PM ETUpcoming EarningsInhibrx Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Inhibrx Biosciences Earnings HeadlinesInhibrx Biosciences, Inc. (NASDAQ:INBX) Stock Has Average Target Price of $197.50October 3 at 4:15 AM | americanbankingnews.comINBX CEO buys 10,000 shares in September filingOctober 1, 2026 | americanbankingnews.comNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire year. The top five hyperscalers, Amazon, Google, Microsoft, Meta, and Oracle, are projected to spend 800 billion on AI this year and 1.3 trillion next year. Jason Bodner, a former Wall Street trader whose system has flagged stocks like Nvidia, Super Micro Computer, and Vertiv before major run ups, says a new light speed technology called Accelerated AI could be next in line for that spending.October 6 at 1:00 AM | Brownstone Research (Ad)Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Mark Lappe Acquires 5,500 SharesSeptember 30, 2026 | americanbankingnews.comInhibrx Biosciences (NASDAQ:INBX) Stock: Insider Mark Lappe Buys 4,500 SharesSeptember 30, 2026 | americanbankingnews.comInhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingSeptember 29, 2026 | finance.yahoo.comSee More Inhibrx Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx Biosciences and other key companies, straight to your email. Email Address About Inhibrx BiosciencesInhibrx Biosciences (NASDAQ:INBX) is a biotechnology company focused on discovering and developing engineered biologic medicines for serious diseases with limited treatment options. The company’s platform has been used to create multifunctional proteins and antibody-based therapies designed to address targets that may be difficult to treat with conventional drugs. Its leading program was INBRX-101, an engineered recombinant human alpha-1 antitrypsin therapy developed for patients with alpha-1 antitrypsin deficiency-associated lung disease. Inhibrx also advanced additional investigational therapies, including INBRX-109, an antibody-based treatment candidate studied in oncology. These products have been evaluated through clinical development programs rather than commercialized as approved medicines by the company. Inhibrx was founded in 2010 and was based in La Jolla, California. In 2024, Sanofi completed its acquisition of Inhibrx, gaining rights to the company’s principal programs, including INBRX-101. The company’s development activities and clinical programs have been directed primarily toward patients in the United States and other international markets through global research and clinical-trial efforts.View Inhibrx Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
